BioLife Solutions, Inc.

Fundamentals6.0
Price Action6.0
News Sentiment7.0
AI Rating
7.0

Key Drivers

  • Strong liquidity
  • Heavy operating spend
  • Improving quarterly profit

AI
AI Summary

7.0

BLFS has shifted from a balance‑sheet turnaround to an execution story where recurring, higher‑margin BPM sales and the post‑evo cash cushion are the engines for durable revenue and margin expansion, but the investment hinges on management proving it can scale BPM ARPU and diversify away from top‑customer concentration without excessive capex or dilutive M&A. Monitor three specific metrics quarterly—BPM ARPU growth rate, top‑5 customer share, and FCF conversion/capex intensity—as failure on any of these against lofty multiples would likely trigger outsized downside.

BPM
Concentration
Valuation‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Strong liquidity
  • Heavy operating spend
  • Improving quarterly profit

BLFS has strong liquidity and low leverage with improving quarterly profitability but suffers from full‑year operating losses, heavy operating spend, large intangibles, negative annual investing cash flow, and a high valuation that heightens downside risk.

Liquidity
HighValuation

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below short-term average
  • Rising volatility
  • Support under test

Stock is short-term bearish—trading below its last-month average after an ~18% drop from $23.09 to $18.85 with rising volatility and near-term support at $18.15–$18.36 that, if broken, would signal further downside.

bearish
oversold
Support Level: $18.15–$18.36
Resistance Level: $22–$24

~18% decline from $23.09 (2026-02-20) to $18.85 (2026-03-20) with larger day-to-day moves

Sentiment & News

7.0

Key News Insights:

  • Revenue acceleration
  • Strategic refocus
  • Analyst optimism

BioLife is emerging from a turnaround with accelerating revenue and restored profitability, strategic refocus and M&A driving ARPU upside, and rising analyst optimism amid short-term share volatility.

turnaround
volatility

Improving fundamentals and targeted M&A should underpin medium‑term upside, while near‑term price volatility may continue